NIDA Program Officer Dr. David Thomas speaks about the intertwined problems of pain and prescription opioid abuse, as well as the research supported by NIDA and the National Institutes of Health to address these problems.
Researchers report a significant advance in the search for medications that can suppress pain but avoid opioids’ abuse potential and other undesirable CNS effects. A new compound reduces mouse responses in animal models of neurogenic and chronic inflammatory (e.g., arthritic) pain. The compound, called UB937, enhances the natural pain-killing activity of the neurotransmitter anandamide, and exerts its analgesic effects entirely in peripheral tissues, without entering the brain.
June 2012 Illicit drug use in the United States in 2010 was at its highest level since 2002, according to the most recent report from the National Survey on Drug Use and Health. A rise in marijuana use drove the increase. A favorable trend of falling cocaine use continued.
April 2012 New research establishes that benzodiazepines cause addiction in a way similar to that of opioids, cannabinoids, and the club drug GHB. The discovery opens the door to designing new benzodiazepines that counteract anxiety but are not addictive.
New research suggests that differences in tobacco consumption reflect, in part, differences in the functional efficacy of a specific type of receptor in a pathway of the brain. In animal studies, nicotinic acetylcholine receptors with the α5 subunit played a key role in producing aversive responses to nicotine, thereby dissuading further consumption of the drug.
March 2008 Describes a new research finding indicating that the antidepressant sertraline (Zoloft), prescribed to relieve depression during the methamphetamine withdrawal process, may make quitting harder.
April 2007 Presents results of a pilot study to investigate the safety and efficacy of a new long-lasting injectable formulation of naltrexone to treat of heroin addiction in an outpatient setting.
October 2006 Presents findings from a clinical trial comparing ultrarapid, anesthesia-assisted detoxification with detoxification by traditional methods among patients addicted to heroin.